<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="2368">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 10, 2022</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02263235</url>
  </required_header>
  <id_info>
    <org_study_id>8652</org_study_id>
    <nct_id>NCT02263235</nct_id>
  </id_info>
  <brief_title>In Vivo Alzheimer Proteomics</brief_title>
  <acronym>PROMARA</acronym>
  <official_title>Use of Targeted Quantitative Proteomics and Metabolic Labelling With Stable Isotopes for the Diagnosis and the Investigation of Neurological Disorders and in Particular Alzheimer Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Montpellier</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Assistance Publique - Hôpitaux de Paris</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Hospital, Clermont-Ferrand</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>International Atomic Energy Agency</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital, Montpellier</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      In France, an estimated 860 000 patients are affected by Alzheimer Disease (AD) which&#xD;
      represents, as in other developed countries, a major public health issue. In many cases, AD&#xD;
      diagnosis is uncertain and its clinical evolution unpredictable. The exactitude of the&#xD;
      diagnosis is however particularly important in the perspective of the validation and use of&#xD;
      new therapeutic strategies in AD. Detection of cerebrospinal fluid (CSF) diagnosis biomarkers&#xD;
      fell short in the detection, of atypical/mixed cases, of some differential diagnosis, and in&#xD;
      differentiating rapid or slow clinical evolutions. Hence, CSF analysis gives a unique&#xD;
      opportunity to detect and validate biomarkers in many neurological disorders. Nevertheless,&#xD;
      in medical practice, CSF biological analysis is currently limited to a small number of&#xD;
      analytes.Quantitative and targeted mass spectrometry, especially operated in the Multiple&#xD;
      reaction monitoring mode (MRM), represents an alternative to immunodetection and could be&#xD;
      used to detect specific biomarkers in complex matrices such as plasma by specifically&#xD;
      discriminating the proteotypic peptides corresponding to each proteins. Mass spectrometry has&#xD;
      also the ability to distinguish and quantify isotopically labelled and unlabeled selected&#xD;
      targets. This ability was used in a publication by the group of R. Bateman (Washington&#xD;
      University, St Louis, USA) who could, after administering stable isotope-labelled leucine,&#xD;
      evaluate Ab synthesis and clearance in humans. This approach has an enormous potential to&#xD;
      study the metabolism of proteins within the human CNS and consequently help in the&#xD;
      understanding and diagnosis of neurological disorders.The main objective of this program is&#xD;
      set up a targeted quantitative mass spectrometry method for existing and stable&#xD;
      isotope-labelled CSF biomarkers in the neurological field; exploit this approach for&#xD;
      diagnostic purpurses and to gain knowledge in the pathophysiology of diseases.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    end of the inclusion period&#xD;
  </why_stopped>
  <start_date type="Actual">October 8, 2013</start_date>
  <completion_date type="Actual">May 22, 2018</completion_date>
  <primary_completion_date type="Actual">May 22, 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>C13 Leucine incorporation in Amyloid peptides (1-40, 1-42) at different time points (in %)</measure>
    <time_frame>1.5 years</time_frame>
    <description>Analysis of labelled samples with mass spectrometry. Data generated will be studied to validate the experimental model and understand the pathophysiology of neurological disorders. A collection of labelled biological samples will also be generated.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>C13 Leucine incorporation in detectable peptides generated after trypsin digestion of biological fluids from patients (CSF, blood, urine, saliva) (in %)</measure>
    <time_frame>1.5 years</time_frame>
    <description>C13 Leucine incorporation in detectable peptides generated after trypsin digestion of biological fluids from patients (CSF, blood, urine, saliva) (in %)</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">89</enrollment>
  <condition>Probable Alzheimer Disease</condition>
  <condition>Parkinson Disease</condition>
  <condition>Neurological Disease Without Cognitive Degradation</condition>
  <condition>Brain Trauma</condition>
  <condition>Acute Hydrocephaly</condition>
  <arm_group>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>60 patients (20 probable AD, 20 Parkinson Disease (PK), 20 neurological disease without cognitive degradation)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>20 patients (patients with brain trauma, acute hydrocephaly), with temporary derivation of the CSF</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>30 patients (15 probable AD, 15 neurological disease without cognitive degradation)</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>administration of stable isotope-labelled leucine-</intervention_name>
    <description>- administration of stable isotope-labelled leucine : by drip, for group 2A and group 2B. Group 1 (control group) : 1 collection of CSF. Group 2B : 4 collections of CSF, 24 hours after administration of stable isotope-labelled leucin. Group 2A (patients with brain trauma, acute hydrocephaly) : continuous collection of CSF, for 24 to 36 hours</description>
    <arm_group_label>Group 2A</arm_group_label>
    <arm_group_label>Group 2B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>collection of CSF, blood, urine, saliva</intervention_name>
    <description>- administration of stable isotope-labelled leucine : by drip, for group 2A and group 2B. Group 1 (control group) : 1 collection of CSF. Group 2B : 4 collections of CSF, 24 hours after administration of stable isotope-labelled leucin. Group 2A (patients with brain trauma, acute hydrocephaly) : continuous collection of CSF, for 24 to 36 hours</description>
    <arm_group_label>Group 1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Reports written consent, informed and signed by the patient and a trusted person&#xD;
&#xD;
          -  Subject member or beneficiary of a social security system&#xD;
&#xD;
        Specific criteria for group 1 and 2B :&#xD;
&#xD;
          -  Age between 55 and 85 years old for patients&#xD;
&#xD;
          -  Subject with AD or other neurodegenerative disease (frontotemporal dementia, dementia&#xD;
             with Lewy bodies, Parkinson disease)&#xD;
&#xD;
          -  Subjects with chronic adult hydrocephalus (HCA) requiring depletion lumbar puncture&#xD;
             (PL)&#xD;
&#xD;
        Specific criteria for group 2A :&#xD;
&#xD;
        - Adult patient requiring neurosurgery with CSF shunt (subject with brain trauma, acute&#xD;
        hydrocephaly) and favorable evolution that allows removal of the shunt&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patient deprived of liberty by judicial or administrative decision&#xD;
&#xD;
          -  Major protected by law&#xD;
&#xD;
          -  Pregnancy, women of childbearing age with risk of pregnancy, or breast-feeding&#xD;
&#xD;
          -  Presence of a transmissible viral disease (HlV, hepatitis B and C)&#xD;
&#xD;
          -  Patient included in a clinical trial&#xD;
&#xD;
          -  lnadequate cardiac, hepatic or severe renal disfunction&#xD;
&#xD;
          -  Disease amino acid metabolism (Leucinose..)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Information clinical and para-clinical insufficient or unavailable&#xD;
&#xD;
          -  Patient deprived of liberty by judicial or administrative decision&#xD;
&#xD;
          -  Major protected by law&#xD;
&#xD;
          -  Pregnancy, women of childbearing age with risk of pregnancy, or breast&#xD;
&#xD;
          -  feeding&#xD;
&#xD;
          -  Presence of a transmissible viral disease (HIV, hepatitis B and C)&#xD;
&#xD;
          -  Patient included in a clinical trial&#xD;
&#xD;
          -  Patient exclusion period relative to another protocol or for which the maximum annual&#xD;
             compensation of 4500€ has been reached&#xD;
&#xD;
          -  Inadequate cardiac, hepatic or severe renal&#xD;
&#xD;
          -  Disease amino acid metabolism (Leucinose..)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>55 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sylvain Lehmann, PU-PH</last_name>
    <role>Principal Investigator</role>
    <affiliation>Laboratoire de Biochimie et Protéomique Clinique, IRMB St Eloi, CHRU de Montpellier</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Laboratoire de Biochimie et Protéomique Clinique, CHU Montpellier</name>
      <address>
        <city>Montpellier</city>
        <zip>34295</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>December 2021</verification_date>
  <study_first_submitted>September 18, 2014</study_first_submitted>
  <study_first_submitted_qc>October 7, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 13, 2014</study_first_posted>
  <last_update_submitted>December 27, 2021</last_update_submitted>
  <last_update_submitted_qc>December 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">December 28, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Alzheimer disease (AD)</keyword>
  <keyword>diagnosis biomarkers</keyword>
  <keyword>cerebrospinal fluid (CSF)</keyword>
  <keyword>targeted quantitative proteomics</keyword>
  <keyword>mass spectrometry</keyword>
  <keyword>stable isotope-labelled leucine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Parkinson Disease</mesh_term>
    <mesh_term>Alzheimer Disease</mesh_term>
    <mesh_term>Nervous System Diseases</mesh_term>
    <mesh_term>Brain Injuries, Traumatic</mesh_term>
    <mesh_term>Hydrocephalus</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

